Q32 Bio (QTTB) Income towards Parent Company (2017 - 2026)
Q32 Bio's (QTTB) quarterly Income towards Parent Company came in at -$16.1 million in Q1 2026, down 45.83% year-on-year from -$29.7 million in Q1 2025, and down 127.87% quarter-over-quarter from $57.7 million in Q4 2025.
Q32 Bio (QTTB) Income towards Parent Company (2017 - 2026) Analysis & Trends
Q32 Bio's Income towards Parent Company history runs 10 years deep, the most recent figure standing at -$16.1 million for Q1 2026.
- On a quarterly basis, Income towards Parent Company fell 45.83% year-over-year to -$16.1 million in Q1 2026; TTM through Mar 2026 was $24.8 million, a 142.45% increase from a year earlier, with the FY2025 full-year figure at $29.8 million, up 164.68% from the prior year.
- Income towards Parent Company retreated to -$16.1 million in Q1 2026 per QTTB's latest filing, from $57.7 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $92.7 million in Q1 2022 and bottomed at -$34.6 million in Q4 2022.
- The 5-year median for Income towards Parent Company is -$14.0 million (2023), against an average of -$5.2 million.
- Across the five-year window, Income towards Parent Company soared 8738.96% in 2022 and tumbled 1015.44% in 2025, its largest moves.
- Year by year, Income towards Parent Company stood at -$34.6 million in 2022, then advanced by 21.48% to -$27.1 million in 2023, then soared by 47.7% to -$14.2 million in 2024, then soared by 506.86% to $57.7 million in 2025, then plunged by 127.87% to -$16.1 million in 2026.
- Per Business Quant, the three latest QTTB Income towards Parent Company figures stand at -$16.1 million (Q1 2026), $57.7 million (Q4 2025), and -$7.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Q32 Bio | 215.94 Mn | 165.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.09 Mn |
| Dec 31, 2025 | 57.73 Mn |
| Sep 30, 2025 | -7.39 Mn |
| Jun 30, 2025 | -9.49 Mn |
| Mar 31, 2025 | -11.03 Mn |
| Dec 31, 2024 | -14.19 Mn |
| Sep 30, 2024 | -17.60 Mn |
| Jun 30, 2024 | -15.53 Mn |
| Mar 31, 2024 | 1.21 Mn |
| Dec 31, 2023 | -27.13 Mn |
| Sep 30, 2023 | -13.97 Mn |
| Jun 30, 2023 | -5.81 Mn |
| Mar 31, 2023 | -6.84 Mn |
| Dec 31, 2022 | -34.56 Mn |
| Sep 30, 2022 | -31.64 Mn |
| Jun 30, 2022 | -27.94 Mn |
| Mar 31, 2022 | 92.70 Mn |
| Dec 31, 2021 | -13.47 Mn |
| Sep 30, 2021 | -30.61 Mn |
| Jun 30, 2021 | -30.50 Mn |